Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphomaGlobeNewsWire • 06/06/23
Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare ConferenceGlobeNewsWire • 05/31/23
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/04/23
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial ResultsGlobeNewsWire • 05/04/23
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial ResultsGlobeNewsWire • 04/27/23
Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 04/27/23
Oncternal Therapeutics Participating in Oppenheimer & Co.'s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid TumorsGlobeNewsWire • 04/13/23
Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025GlobeNewsWire • 04/03/23
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/09/23
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/02/23
Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 03/02/23
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 03/01/23
Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of DirectorsGlobeNewsWire • 01/04/23
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022GlobeNewsWire • 12/10/22
Oncternal Therapeutics (ONCT) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/03/22
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/03/22
Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022GlobeNewsWire • 11/03/22